C2N Diagnostics   Report issue

For profit Phase 1
Founded: St Louis MO United States (2007)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2015
NCT02494024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

abbv-8e12 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Paralysis (Phase 1)

Supranuclear Palsy, Progressive (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1